Exploring language disorders in patients with psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the language disorders present in patients with psychotic disorders, focusing on how these disorders affect communication across various linguistic domains such as phonology, lexicon, semantics, morphosyntax, and pragmatics. It aims to characterize these language difficulties and assess their interactions with other symptoms of psychosis, particularly thought disorders and neuropsychological symptoms. The study will involve language assessments and standardized interviews to gather comprehensive data on the participants' language capabilities and mental state. Participants will include individuals diagnosed with schizophrenia and those at risk of developing psychosis, treated at the Psychotherapeutic Center of Nancy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All Groups:

  * Patient affiliated or entitled to a social security scheme
  * Patient having received informed information on the study and having co-signed, with the investigator, a consent to participate in the study
  * For minor participants, at least one of the parents or holders of parental authority having been informed of the study, having received the information note relating to it and not having objected to the participation of his or her child
  * Native language: French
* ARMS and FEP Patient Group:

  * Age between 16 and 35 years old
  * Present the criteria for EMRP or FEP as defined by the Comprehensive Assessment of At Risk Mental State (CAARMS) or present the criteria for Disorders of the course of thought to the items of the Schizophrenia Proneness Instrument (SPI-A)
* Patients with schizophrenia group:

  * Age between 16 and 55 years old
  * Patient with diagnostic criteria for schizophrenia, as defined by DSM V (American Psychiatric Association, 2015)
  * Present the criteria for Disorganization of Speech and Formal Thought Disorder as defined by the Thinking, Language and Communication (TLC) Rating Scale.
* Healthy Volunteers Group:

  * Age between 16 and 55 years old
  * Parental authorization (of both parents) to participate in the study for minor patients

Exclusion Criteria:

* All groups:

  * Pregnant, parturient or nursing mother
  * Person deprived of liberty by a judicial or administrative decision
  * Person in a life-threatening emergency
  * Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  * Adult person unable to express their consent and who is not the subject of a legal protection measure
  * Impairment of the subject making it difficult, if not impossible, for them to participate in the trial or to understand the information given to them
  * Abuse or dependence of any substance according to DSM V criteria excluding cannabis
* Healthy Volunteers Group:

  * Evolving psychiatric pathology (axis I of the DSM IV, measured at the MINI) excluding anxiety disorder
  * Presence of developmental disorder of oral language or written language revealed on clinical examination.

Where it's running

• Centre Psychothérapeutique de Nancy
  Laxou, France, France Recruiting

Study contacts

• Principal investigator: Florent Bernardin, PhD — Centre psychothérapeutique de Nancy
• Study coordinator: Anaëlle PAJAUD
• Email: Anaelle.PAJAUD@cpn-laxou.com
• Phone: 0383260863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

• Precision brain stimulation to reduce cannabis craving in people with schizophrenia

  This trial tests whether targeted brain stimulation can reduce cannabis craving and improve thinking in people with schizophrenia who currently use cannabis.

  Recruiting Vanderbilt University Medical Center · Nashville, Tennessee · NCT07196462

• Improving rehabilitation for veterans with serious mental illness

  This study is testing a new computer program to help veterans with serious mental illnesses improve their thinking and daily life skills.

  Recruiting VA Office of Research and Development · San Diego, California · NCT06586164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.